University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

John Park, M.D.

Oncologist and breast cancer specialist

Dr. John W. Park is an oncologist who specializes in breast cancer treatment and research. In his laboratory, Park works to develop novel technologies to study and treat cancer. His research includes new forms of immunotherapy such as antibodies, immunoliposomes and vaccines targeted against cancer cells. He also conducts clinical trials to evaluate new technologies and treatments for cancer patients. Park was also a visiting scientist at Genentech, Inc. where he performed research on Her2/Neu, a receptor protein on breast cancer cells, and Herceptin, a new treatment that acts as an antibody to Her2Neu. Park joined the UCSF Medical Center in 1992 as an assistant professor in the Department of Medicine.

Clinics

Carol Franc Buck Breast Care Center
1600 Divisadero St., Second Floor
San Francisco, CA 94115
Phone: (415) 353-7070
Surgery Fax: (415) 353-7050
Oncology Fax: (415) 353-7692

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about John Park

Education

Stanford University 1986

Residencies

UCLA, Internal Medicine 1989

Fellowships

UCSF, Hematology 1992
UCSF, Medical Oncology 1992

Selected Research and Publications

  1. Magbanua MJ, Melisko M, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, Ryazantsev A, Au A, Scott JH, Park JW. Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Cancer Res. 2013 Dec 1; 73(23):7134-43.
  2. Magbanua MJ, Park JW. Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling. Methods. 2013 Dec 1; 64(2):114-8.
  3. Weng KC, Hashizume R, Noble CO, Serwer LP, Drummond DC, Kirpotin DB, Kuwabara AM, Chao LX, Chen FF, James CD, Park JW. Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models. Nanomedicine (Lond). 2013 Dec; 8(12):1913-25.
  4. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 1; 19(11):2817-23.
  5. Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, Pinkel D, Rugo HS, Park JW. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res. 2013 Jan 1; 73(1):30-40.
  6. Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, van't Veer L, Esserman LJ. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Res Treat. 2012 Oct; 135(3):913-22.
  7. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, Ryan CJ, Park JW. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer. 2012; 12:78.
  8. Gedda L, Fondell A, Lundqvist H, Park JW, Edwards K. Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles. J Nucl Med. 2012 Mar; 53(3):480-7.
  9. Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(1):13-20.
  10. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2724-9.
  11. Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, Prados MD, Park JW, James CD. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro Oncol. 2011 Dec; 13(12):1288-95.
  12. Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat. 2011 Sep; 129(2):607-16.
  13. Park JW. Disseminated tumor cells: the method is the message. Breast Cancer Res Treat. 2011 Feb; 125(3):739-40.
  14. Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Larson RF, Yamashita Y, Krauze MT, Forsayeth J, Noble CO, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS. Canine spontaneous glioma: a translational model system for convection-enhanced delivery. Neuro Oncol. 2010 Sep; 12(9):928-40.
  15. Barok M, Balazs M, Lazar V, Rakosy Z, Toth E, Treszl A, Vereb G, Colbern GT, Park JW, Szollosi J. Characterization of a novel, trastuzumab resistant human breast cancer cell line. Front Biosci (Elite Ed). 2010; 2:627-40.
  16. Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, Fornier M, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA, Dickler MN. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol. 2010 Feb 1; 28(4):628-33.
  17. Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, Sims RB, Lin LR, Frohlich MW, Park JW. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res. 2009 Sep 15; 15(18):5937-44.
  18. Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release. 2010 Jan 4; 141(1):13-21.
  19. Lang JE, Magbanua MJ, Scott JH, Makrigiorgos GM, Wang G, Federman S, Esserman LJ, Park JW, Haqq CM. A comparison of RNA amplification techniques at sub-nanogram input concentration. BMC Genomics. 2009; 10:326.
  20. Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, Drummond DC. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol. 2009 Sep; 64(4):741-51.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.